Interim report Q1 2025
Werte in diesem Artikel
Strong start to the year and confirmed full-year outlook
Ester Baiget, President & CEO: "We delivered strong sales growth and earnings in the first quarter, with all four sales areas showing double-digit growth. Growth was driven by strong innovation especially in emerging markets, and with a continued broad pull for our solutions in developed markets. Synergies are materializing as expected and we are confirming the full-year outlook. We continue to see solid demand across the business, and our regional presence and resilient global setup enable us to respond with agility in these dynamic times”.
- Strong organic sales growth of 11% including ~1pp from price. All sales areas with double-digit organic sales growth. Emerging markets organic sales growth at 15% and developed markets at 9%.
- Adjusted EBITDA margin at 38.3%, up by 310bps.
- Adjusted net profit increased by 27%.
- NIBD/EBITDA at 1.1x.
- Announcement on February 11 to acquire dsm-firmenich’s part of the feed enzyme alliance at a EUR 1.5bn cash consideration, expected to close in the second quarter.
- Andrew Taylor announced on April 22 as new EVP Food & Beverages, joining the company no later than September 1, 2025.
- 2025 outlook maintained: 5-8% organic sales growth (6-9% excluding the exit from certain countries) and an adjusted EBITDA margin between 37-38% despite current currency headwinds.
Please read the full announcement in PDF
Attachment
Ausgewählte Hebelprodukte auf Novozymes A-S (B)
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Novozymes A-S (B)
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle Novozymes A-S (B) Aktie News
Novozymes A-S (B) Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Novozymes A-S (B) nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
| Datum | Rating | Analyst | |
|---|---|---|---|
| 17.10.12 | Novozymes hold | Deutsche Bank AG | |
| 03.09.12 | Novozymes buy | ING | |
| 28.08.12 | Novozymes overweight | Morgan Stanley | |
| 09.08.12 | Novozymes overweight | Morgan Stanley | |
| 22.06.12 | Novozymes overweight | Morgan Stanley |